OPKO November 2020 NASDAQ: OPK Forward Looking Statements This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "potential," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the mar ...

OPKO Forward Looking Statements This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "potential," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the market for and sales of our p ...

OPKO Health, Inc. (NASDAQ:OPK) Q2 2020 Earnings Conference Call October 29, 2020 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Phil Frost - Chairman and Chief Executive Officer Steve Rubin - Executive Vice President, Administration Jon Cohen - Senior Vice President, OPKO Health; Executive Chairman, BioReference Laboratories Adam Logal - Senior Vice President and Chief Financial Officer Charles Bishop - Chief Executive Officer, OPKO Renal Conference Call Participants Maury Raycroft - ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-33528 OPKO Health, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdicti ...

OPKO Health, Inc. (NASDAQ:OPK) H. C. Wainwright 22nd Annual Global Investment Conference Call September 15, 2020 10:00 AM ET Company Participants Steven D. Rubin - EVP, Administration Jon Cohen - Senior Vice President Conference Call Participants Stephen Bersey - H.C. Wainwright Stephen Bersey Hello. My name is Stephen Bersey. I'm an equity research associate here at H.C. Wainwright. Our next presenters are Steven D. Rubin, who's Executive Vice President of OPKO Health; and Jon Cohen, Senior Vice President ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-33528 OPKO Health, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of ...

OPKO Health, Inc. (NASDAQ:OPK) Q2 2020 Earnings Conference Call July 30, 2020 4:45 PM ET Company Participants Yvonne Briggs – LHA, Investor Relations Phillip Frost – Chairman and Chief Executive Officer Steve Rubin – Executive Vice President Jon Cohen – Senior Vice President-OPKO Health and Executive Chairman-BioReference Laboratories Adam Logal – Chief Financial Officer Conference Call Participants Maury Raycroft – Jefferies Dana Flanders – Guggenheim Yale Jen – Laidlaw & Company Ted Tenthoff – Piper Sandl ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-33528 OPKO Health, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-33528 OPKO Health, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Inc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the p ...